The National Institutes of Health is considering granting an Exclusive Patent License to Iovance Biotherapeutics, Inc. for inventions related to cancer treatment. This involves patents for a combination of T cell therapy and vaccination designed to boost the immune system's ability to fight cancer. The proposed license will cover the development and commercialization of these treatments for human cancer patients. The public can submit comments or objections to this proposal by December 17, 2024.
Simple Explanation
The National Institutes of Health is thinking about letting a company called Iovance Biotherapeutics use a special invention that helps the body fight cancer better. This means only Iovance can use this idea to make medicines, and people can tell the NIH what they think about this plan until December 17, 2024.